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Introduction: Acute leukemia is rare in pregnancy. The importance of promptly diagnosing and treating this
disease in pregnancy stems from its life-threatening potential, both to the mother and fetus.
Case presentation: We report a case of relapse of acute myeloid leukemia at 23 weeks of pregnancy in a 24-year-old
Albanian woman. Our patient categorically refused chemotherapy treatment, and in her 35th week of gestation, severe
hemorrhagic diathesis rapidly developed. The manifestation and course of this life-threatening complication posed
therapeutic challenges for the attending medical team.
Conclusion: Based both on our experience and the results of other gynecological studies, there exists a strong
indication that the earlier a patient’s chemotherapy treatment begins, the better the maternal outcome. We support
chemotherapy for patients who are pregnant presenting with such illness. The present case report testifies that refusal
of chemotherapy by such patients is a high-risk decision.
Keywords: Chemotherapy, Coagulopathy, Leukemia, PregnancyIntroduction
One in 1000 pregnancies coexist with malignant disease
[1,2]. The incidence of leukemia in pregnancy is one in
75,000 to 100,000 pregnancies [3]. The majority of cases
of leukemia diagnosed during pregnancy are acute [4-6].
Acute leukemia normally requires prompt treatment
despite significant risks of pregnancy loss and birth de-
fects, especially if chemotherapy is given during the first
trimester of pregnancy. Evidence suggests that treatment
postponement until the post-partum period is associated
with increased maternal mortality [7].
The association of malignancy with pregnancy always
creates a serious dilemma for both the pregnant woman
and the medical team. Although rare, evidence from case
reports of patients who are pregnant who have acute
leukemia, including cases of relapse, provides very help-
ful treatment information in such medical dilemmas.
Case presentation
At 23 weeks of gestation, a pregnant 24-year-old Albanian
woman, gravida 3, para 2, was admitted to our hematology* Correspondence: drsyheda@yahoo.com
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reproduction in any medium, provided the orclinic with chest pain, nosebleeds, gingival bleeding,
general weakness, and fatigue. One year prior to admis-
sion, she had been diagnosed as having acute myeloid
leukemia and was treated with doxorubicin and cytarabine
according to our chemotherapy protocol.
Six months after chemotherapy, while in remission,
she became pregnant. Her pregnancy progressed with
no complications until the 23rd week of gestation. Her
general health became impaired, and laboratory test
results confirmed a relapse of acute myeloid leukemia.
Her obstetric examination findings and fetal sonography
results were normal and appropriately correlated with
the gestational age. Blood count results revealed that
her maternal hemoglobin (Hgb) level was 8.5g/dL, platelet
(Plt) count was 65×109plt/L, red blood cell (RBC) count
was 2.8×109 cells/L, white blood cell (WBC) count was
45×109 cells/L with 50 percent blast cells, hematocrit
(Hct) was 29 percent, and sedimentation rate was
35mm. Her urea and creatinine levels were within the
normal ranges.
The attending medical team included a hematologist,
an oncologist, and an obstetrician. After analyzing our
patient’s history, medical examination results, and labora-
tory data, the medical team proposed that our patient
begin chemotherapy treatment without delay. In spite ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 2 Operative wound bleeding. Two hours after the
Cesarean section, our patient developed the following hemorrhagic
manifestations: gingival bleeding, generalized purpura and
petechiae, and operative wound bleeding. Laboratory test results
showed a platelet count of 8×109plt/L.
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patient, she categorically refused any kind of chemo-
therapy treatment. Our patient’s decision was thera-
peutically challenging for the medical team.
Our patient was frequently followed up with clinical
assessments and laboratory tests. At 32 weeks of gesta-
tion, urine culture results showed an Escherichia coli
infection, which was treated with ceftriaxone. A blood
count performed at this time revealed a RBC count of
2.5×109 cells/L, WBC count of 30.8×109 cells/L, Plt
count of 41×109plt/L, Hgb level of 6.6g/dL, and Hct of
22.2 percent.
Supportive therapy including fresh whole blood and
blood product transfusions was administered to stabilize
our patient. The fetal condition was closely monitored
using ultrasound and later using cardiotocography. At
34 weeks of gestation, a course of betamethasone was
administered. The ultrasound measurements showed slight
intra-uterine growth restriction, but no fetal distress.
At 35 weeks of gestation, our patient’s general health
declined and there was evidence of fetal distress. Labora-
tory test results at this time showed the following alter-
ations: RBC, 3.1×1012 cells/L; WBC, 38.6×109 cells/L;
Hgb, 10g/dL; Hct, 28 percent; Plt, 10×109plt/L; lymphocytes,
12.8 percent; monocytes, 10.4 percent; and granulocytes,
76.8 percent. Coagulation analysis revealed a prothrombin
time of 16.8 seconds (reference range, 9.8 to 13.4 seconds)
and an activated partial thromboplastin time of 24.0
seconds (reference range, 27.9 to 41.6 seconds).
An emergency Caesarean section was performed, and
a healthy baby was delivered (weight, 1900g; Apgar score,
5/6). During the operation, 1U of fresh whole blood
and 3U of fresh plasma were transfused because of
intra-operative bleeding. Then, two hours after the
Caesarean section, our patient developed generalized
purpura (Figure 1) and petechiae, gingival bleeding, andFigure 1 Cutaneous bleeding manifestations.operative wound bleeding (Figure 2). Approximately 300mL
of blood was drained from the Douglas pouch. Laboratory
test results showed a Plt count of 8×109plt/L. After con-
sulting with our hematologist, we administered another
2U of blood, 8U of fresh plasma, and 15U of platelets.
Five days after the Cesarean section, our patient was
transferred to our Hematology Clinic, where she agreed
to undergo chemotherapy.
Six days after delivery, she began chemotherapy com-
prising an anti-metabolite and anthracycline, namely
cytarabine (200mg/m2 for seven days) and doxorubicin
(60mg/m2 for three days), respectively. Close neonatal
follow-up revealed normal development. To date, our
patient remains in complete remission, and the develop-
ment of her baby, now three years of age, has progressed
with no complications.Discussion
The actual incidence of leukemia in pregnancy is not
well known. It is estimated to range from one in 75,000
to 100,000 pregnant women [8]. Most cases of leukemia
associated with pregnancy are acute, while less than
10 percent of all cases are chronic. Among cases of
acute leukemia, myeloid leukemia occurs twice as often
as acute lymphoblastic leukemia.
Three unique subgroups of acute myeloid leukemia
are recognized by the World Health Organization clas-
sification (Table 1): (1) acute myeloid leukemia with
recurrent genetic abnormalities; (2) acute myeloid leukemia
with multi-lineage dysplasia; and (3) therapy-related acute
myeloid leukemia and myelodysplastic syndrome. Cases
that do not satisfy the criteria for any of these sub-
groups or for which no genetic data can be obtained
Table 1 World Health Organization classification of acute myeloid leukemia
Subgroup Type
Acute myeloid leukemia with recurrent genetic abnormalities Acute myeloid leukemia with t(8;21)(q22;q22), (AML1/ETO)cpn
Acute myeloid leukemia with abnormal bone marrow eosinophils
and inv(16)(p13q22) or t(16;16)(p13;q22), (CBFβ/MYH11)
Acute promyelocytic leukemia with t(15;17)(q22;q12), (PML/RARα),
and variants
Acute myeloid leukemia with 11q23 (MLL) abnormalities
Acute myeloid leukemia with multi-lineage dysplasia Following myelodysplastic syndrome or myelodysplastic
syndrome/myeloproliferative disease
Without antecedent myelodysplastic syndrome or myelodysplastic
syndrome/myeloproliferative disease, but with dysplasia in at least
50 percent of cells in two or more myeloid lineages
Therapy-related acute myeloid leukemia and myelodysplastic syndrome Alkylating agent/radiation-related type
Topoisomerase II inhibitor-related type (some may be lymphoid)
Others
Acute myeloid leukemia not otherwise categorized Acute myeloid leukemia, minimally differentiated
Acute myeloid leukemia without maturation
Acute myeloid leukemia with maturation
Acute myelomonocytic leukemia
Acute monoblastic/acute monocytic leukemia
Acute erythroid leukemia (erythroid/myeloid and pure erythroleukemia)
Acute megakaryoblastic leukemia
Acute basophilic leukemia
Acute panmyelosis with myelofibrosis
Myeloid sarcoma
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leukemia, not otherwise categorized [9].
Acute myeloid leukemia may be associated with life-
threatening hemorrhagic diathesis, which is attributed
to disseminated intra-vascular coagulation. Disseminated
intra-vascular coagulation may complicate the course of
leukemia in as many as 50 percent of patients [10]. The
most common leukemia associated with disseminated
intra-vascular coagulation is acute promyelocytic leukemia
followed by acute myelomonocytic leukemia, acute myelo-
blastic leukemia, and acute lymphoblastic leukemia [11].
Acute leukemia is an extremely aggressive disease and
is fatal unless promptly treated [12]. During pregnancy,
acute myeloid leukemia poses an immediate threat to
the lives of both the mother and fetus, making prompt
diagnosis and treatment extremely important [13]. Acute
leukemia requires immediate treatment, regardless of
gestational age. Patients with leukemia should undergo
aggressive chemotherapy until remission is achieved,
regardless of pregnancy. In cases of relapse, the chemo-
therapy should be started without delay. Chemotherapy
during the first trimester is associated with an increased
risk of congenital malformations; thus, abortion (termin-
ation of the pregnancy) should be considered. Standardanti-leukemia treatment can be safely administered during
the second and third trimesters of pregnancy [14].
Evidence indicates that maternal and fetal outcomes
improve substantially with medical treatment. Therefore,
advocating such chemotherapy treatments would be both
physically beneficial for pregnant women as well as helpful
for mothers during their decision-making process.Conclusions
Our patient’s case is an example of fertility preservation
following anti-leukemia chemotherapy. Our patient became
pregnant during her remission phase, six months after
completion of chemotherapy. Our patient’s case also
suggests that pregnancy might be associated with an
increased risk of acute leukemia relapse. The maternal
decision to categorically refuse chemotherapy despite the
associated risks also underlines the therapeutic challenge
faced by the attending medical team in such cases. In light
of other reports that have documented similar successfully
treated cases, along with our experience of treatment
refusal followed by life-threatening hemorrhagic diathesis,
we promote chemotherapy for patients who are pregnant
who are diagnosed as having acute myeloid leukemia.
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